Canada markets closed

BioSyent Inc. (BIOYF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
5.50-0.29 (-5.01%)
At close: 12:51PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close5.79
Bid0.00 x 0
Ask0.00 x 0
Day's Range5.50 - 5.50
52 Week Range5.13 - 7.71
Avg. Volume2,251
Market Cap71.142M
Beta (5Y Monthly)1.00
PE Ratio (TTM)20.37
EPS (TTM)0.27
Earnings DateNov. 24, 2021 - Nov. 29, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Simply Wall St.

    Is There An Opportunity With BioSyent Inc.'s (CVE:RX) 42% Undervaluation?

    Today we will run through one way of estimating the intrinsic value of BioSyent Inc. ( CVE:RX ) by taking the forecast...

  • GlobeNewswire

    BioSyent Releases Q2 and H1 2021 Financial Results

    MISSISSAUGA, Ontario, Aug. 25, 2021 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today its financial results for the three and six months ended June 30, 2021. Key highlights include: Second quarter (Q2) 2021 Net Revenues of $7,289,254 increased by 53% versus Q2 2020First half (H1) 2021 Net Revenues of $14,709,143 increased by 36% versus H1 2020Record quarterly Canadian Pharmaceutical Net Revenues in Q2 2021 of $6,670,322 increased by 51% versus Q2 2020H1 2021 Canadian

  • GlobeNewswire

    BioSyent Schedules Q2 and H1 2021 Earnings Release for August 25, 2021

    MISSISSAUGA, Ontario, Aug. 17, 2021 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) will be reporting its financial results for the three and six months ended June 30, 2021 on Wednesday, August 25, 2021 at 8:00am ET. A presentation on the Company’s second quarter and first half 2021 results by René Goehrum, BioSyent President and CEO, will also be available on the Company’s website on the date of release. About BioSyent Inc. Listed on the TSX Venture Exchange under